Research summary ·
Validity of the 2023 ACR/EULAR APS classification criteria for paediatric primary APS: inputs from a systematic literature review.
Written based on 1 research study on PubMed, searched on 15 Nov 2026.
What was studied
In 2023, new rules were set out to class people as having APS. These rules were tested in adults, but data in kids are scarce. This team looked at kids with primary APS. They searched past studies and pulled out data on each child. They pooled the data to see how often the rules caught APS. They also checked earlier rules from 2006, called the Sapporo rules.
What they found
The team found 118 studies, with 148 kids in total. Blood clots were the main problem reported in these kids. Many also had other signs besides clots. The most common other sign was a low platelet count. The 2006 rules picked up APS more often than the 2023 rules. Most kids missed by the new rules did not meet the lab parts.
What it means for patients
The authors say the 2023 rules fall short for kids with primary APS. Adding signs other than clots did help class these kids. But lab cut-offs and some missing signs seen in kids remain a problem. The authors say APS in kids and adults only partly overlaps. They call for new rules made just for kids. Such rules could help describe the illness and aid research.
Why it is not certain yet
The data came from past published reports, not from a new study. A review can only be as good as the studies in it. Only kids with primary APS were looked at. The abstract does not give details on how the reports differed.
Source
Validity of the 2023 ACR/EULAR APS classification criteria for paediatric primary APS: inputs from a systematic literature review.
PubMed · PMID 42902782We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Antiphospholipid syndrome publications